ABBVIE
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT02531178
- Locations
- 🇩🇪
Site Reference ID/Investigator# 139394, Berlin, Germany
ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
- Conditions
- Interventions
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 650
- Registration Number
- NCT02517515
ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 104
- Registration Number
- NCT02517528
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 65
- Registration Number
- NCT02513459
- Locations
- 🇧🇪
AZ-Delta /ID# 154983, Roeselare, Belgium
🇺🇸MGG Group, Inc.Chevy Chase Clinical Research /ID# 155068, Chevy Chase, Maryland, United States
🇪🇸Hospital Univ de la Princesa /ID# 155065, Madrid, Spain
Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 240
- Registration Number
- NCT02507687
- Locations
- 🇺🇸
Wolstan & Goldberg Eye Associates /ID# 235166, Torrance, California, United States
🇺🇸Trinity Research Group /ID# 234598, Dothan, Alabama, United States
🇺🇸Houston Eye Associates /ID# 237883, Houston, Texas, United States
Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis
- Conditions
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT02506179
- Locations
- 🇨🇦
Bellini Medicine Professional /ID# 144241, Brampton, Ontario, Canada
🇨🇦Oshawa Clinic /ID# 144364, Oshawa, Ontario, Canada
🇨🇦The Ottawa Hospital /ID# 139392, Ottawa, Ontario, Canada
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3
- Registration Number
- NCT02504099
A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice
- Conditions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT02499263
- Locations
- 🇰🇷
Korea University Anam Hospital /ID# 138446, Seoul, Korea, Republic of
🇰🇷Kyungpook National Univ Hosp /ID# 153133, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷St. Vincent's Hospital /ID# 138455, Suwon, Gyeonggido, Korea, Republic of
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 205
- Registration Number
- NCT02499783
Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults
- Conditions
- Interventions
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 46
- Registration Number
- NCT02493855